CCL4 and retinopathy of prematurity: The administration of a neutralizing antibody against MIP-1β inhibits physiological angiogenesis (113); therefore, we believe that MIP-1β has the potential to be a useful inflammatory biomarker of ROP progression or recurrence rather than a therapeutic target molecule.